Article Text

Download PDFPDF
EP237 Survival outcome and disease free survival of locally advanced cervical cancer with CT-detected para-aortic lymph nodes
  1. JK Abrenica and
  2. J Bagadiong
  1. OB-GYN, Jose R. Reyes Memorial Medical Center, Manila, Philippines


Introduction/Background In the Philippines, cervical cancer ranks second in the list of cancers among female and the country’s second leading cause of female cancer deaths. Majority of the patients seek consult with advanced stage of the disease. In the absence of histologically proven lymph node metastasis, imaging may be used to determine patients with para-aortic lymph node metastasis who may benefit with Extended Field Radiation. The aim of this study is to investigate the survival outcome and disease-free survival of advanced cervical cancer with Computed Tomography (CT) Scan detected para-aortic lymph node (PALN) after concurrent chemoradiotherapy using extended field radiotherapy (EFRT) with weekly platinum-based chemotherapy followed by High Dose Brachytherapy.

Methodology This is a retrospective study which included patients diagnosed with locally advanced cervical carcinoma according to the FIGO (stage IB2 - stage IIIB) who had CT detected PALN metastasis and underwent EFRT with weekly chemotherapy followed by brachytherapy at a single institution from January 2002 - December 2015. The 3 year over-all survival outcome (OS) and disease free survival (DFS) of the patients were documented and analyzed.

Results There were 51 patients who satisfied the inclusion criteria and were included in the study. The 3-year OS and DFS rates were 81.3% and 58.6%, respectively. The median survival time was 35.5 months and the median disease free time was 25.04 months.

Conclusion The current recommendation of EFRT with concurrent chemotherapy followed by brachytherapy can be an effective treatment for cervical cancer patients with CT-detected para-aortic lymph node metastasis with 81.3% 3 year survival outcome. Patients with Non-Squamous Cell Carcinoma have higher risks of recurrence, with central tumor recurrence being the most common site.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.